CS Pramesh, MS, FRCS, on Opportunities in India: A Perspective From a Low-Middle Income Country

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

The Interventional Pharmacoeconomic Toolbox Panel Discussion

David A. Hyman, MD, JD, on Inclusive Shared Savings

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Oct

Today In Oncology

CS Pramesh, MS, FRCS, on Opportunities in India: A Perspective From a Low-Middle Income Country

Related Videos

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

The Interventional Pharmacoeconomic Toolbox Panel Discussion

David A. Hyman, MD, JD, on Inclusive Shared Savings

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Omega-3 EPA Linked to Longer Survival After Surgery for Colorectal Cancer Liver Metastases

High-Risk Melanoma Personalized mRNA Vaccine Plus Immunotherapy Reduces Risk of Recurrence After Surgery

FDA Approves Talazoparib With Enzalutamide for Certain Metastatic HRR-Mutated Prostate Cancers

GLP-1 RA Use Lower Among Adults With Both Diabetes and a History of Cancer

Triplet Therapy With Abiraterone Improves OS Long-Term in Metastatic Castration-Sensitive Prostate Cancer